Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo responses and variability in Phase 2 trials but still promoted Phase 3 trial success. Shareholders who bought stock before April 1, 2024, are urged to contact the law firm to protect their rights. This case highlights potential governance issues affecting investor confidence in Vistagen Therapeutics.
Ipsos has appointed Kelly Beaver as its new Chief Executive Officer, effective immediately, succeeding Jean Laurent Poitou. Kelly Beaver has over 15 years of experience at Ipsos, including leadership roles in the UK and Ireland and global healthcare ...
Ipsos has named Kelly Beaver as its new CEO, effective immediately, succeeding Jean Laurent Poitou. Beaver brings over 15 years of experience within Ipsos, including leadership roles in the UK and global health division. The board praised her experti...
UBS Group AG has reported holding 5,898,317 shares in Bang & Olufsen A/S, representing 4.00% of the company's total share capital and voting rights as of July 27, 2026. This disclosure is made under the Danish Capital Markets Act, indicating UBS's st...
Bekaert continued its share buyback program from July 23 to 29, 2026, purchasing 48,186 shares at an average price of €41.86 per share, totaling over €2 million. The company plans to cancel all repurchased shares, reducing the number of outstanding s...
Forvia, a global automotive technology supplier, announced the availability of its financial report for the first half of 2026. The report, filed with the French market authority, highlights margin expansion and strong net cash flow, confirming the c...
